Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing-Reference-Cited by-同舟云学术

Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing

Published:2017-05 Issue: Volume:107 Page:22-35
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Doble Brett,John Thomas,Thomas David,Fellowes Andrew,Fox Stephen,Lorgelly Paula

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference57 articles.

1. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma;Bronte;Cancer Treat. Rev.,2010

2. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

3. KRAS mutations as prognostic and predictive markers in non-small cell lung cancer;Martin;J. Thorac. Oncol.,2013

4. New targetable oncogenes in non-small-cell lung cancer;Oxnard;J. Clin. Oncol.,2013

5. Crizotinib in ROS1-rearranged non-small-cell lung cancer;Shaw;N. Engl. J. Med.,2014

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Next-generation sequencing impact on cancer care: applications, challenges, and future directions;Frontiers in Genetics;2024-07-09

2. Precision medicine in Thoracic Oncology: understanding disparities to tackle inequities in access;Expert Review of Pharmacoeconomics & Outcomes Research;2023-09-26

3. Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer;Value in Health;2023-01

4. Polygenic risk scores: An overview from bench to bedside for personalised medicine;Frontiers in Genetics;2022-11-11

5. Prediction of the Presence of Targetable Molecular Alteration(s) with Clinico-Metabolic 18 F-FDG PET Radiomics in Non-Asian Lung Adenocarcinoma Patients;Diagnostics;2022-10-10